Duloxetine Gains Wane In U.S. As New India, Other Generic Entrants Disrupt Pricing
This article was originally published in PharmAsia News
Executive Summary
After making handsome gains from selling generic versions of duloxetine Eli Lilly’s blockbuster anti-depression brand Cymbalta, companies are under pressure from the second wave of offerings.